Hong Kong Stock Alert | CSTONE PHARMA-B (02616) Rises Over 3% as Company to Present PD-1/VEGF/CTLA-4 Trispecific Antibody Phase I Dose Escalation Clinical Data at ESMO Conference

Stock News

Oct 13

CSTONE PHARMA-B (02616) surged over 3%, closing up 2.79% at HK$6.99 with a trading volume of HK$15.38 million as of press time.

On the news front, CSTONE PHARMA-B announced that the 2025 European Society for Medical Oncology (ESMO) Annual Congress will be held from October 17-21, 2025, in Berlin, Germany. Abstracts for the company's core clinical pipeline candidate CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) ongoing Phase I dose escalation clinical data and CS5001 (ROR1 antibody-drug conjugate [ADC]) ongoing Phase Ib clinical study design have been published on the ESMO official website.

The CS2009 abstract covers only baseline Phase I data from 9 patients as of May 8, 2025 (abstract submission deadline), designed to meet ESMO's abstract submission requirements. At the upcoming ESMO conference, CSTONE PHARMA-B will present preliminary Phase I dose escalation clinical research data for CS2009 in approximately 70 patients with advanced solid tumors in poster format. This will mark the first known global clinical data publication for a PD-1/VEGF/CTLA-4 trispecific antibody.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1174643782"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174643782\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174643782?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174643782","market":"hk","top_or_hot":-1,"title":"Hong Kong Stock Alert | CSTONE PHARMA-B (02616) Rises Over 3% as Company to Present PD-1/VEGF/CTLA-4 Trispecific Antibody Phase I Dose Escalation Clinical Data at ESMO Conference","media":"Stock News","content":"<p>CSTONE PHARMA-B (02616) surged over 3%, closing up 2.79% at HK$6.99 with a trading volume of HK$15.38 million as of press time.</p>\n<p>On the news front, CSTONE PHARMA-B announced that the 2025 European Society for Medical Oncology (ESMO) Annual Congress will be held from October 17-21, 2025, in Berlin, Germany. Abstracts for the company's core clinical pipeline candidate CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) ongoing Phase I dose escalation clinical data and CS5001 (ROR1 antibody-drug conjugate [ADC]) ongoing Phase Ib clinical study design have been published on the ESMO official website.</p>\n<p>The CS2009 abstract covers only baseline Phase I data from 9 patients as of May 8, 2025 (abstract submission deadline), designed to meet ESMO's abstract submission requirements. At the upcoming ESMO conference, CSTONE PHARMA-B will present preliminary Phase I dose escalation clinical research data for CS2009 in approximately 70 patients with advanced solid tumors in poster format. This will mark the first known global clinical data publication for a PD-1/VEGF/CTLA-4 trispecific antibody.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | CSTONE PHARMA-B (02616) Rises Over 3% as Company to Present PD-1/VEGF/CTLA-4 Trispecific Antibody Phase I Dose Escalation Clinical Data at ESMO Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | CSTONE PHARMA-B (02616) Rises Over 3% as Company to Present PD-1/VEGF/CTLA-4 Trispecific Antibody Phase I Dose Escalation Clinical Data at ESMO Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-13 09:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSTONE PHARMA-B (02616) surged over 3%, closing up 2.79% at HK$6.99 with a trading volume of HK$15.38 million as of press time.</p>\n<p>On the news front, CSTONE PHARMA-B announced that the 2025 European Society for Medical Oncology (ESMO) Annual Congress will be held from October 17-21, 2025, in Berlin, Germany. Abstracts for the company's core clinical pipeline candidate CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) ongoing Phase I dose escalation clinical data and CS5001 (ROR1 antibody-drug conjugate [ADC]) ongoing Phase Ib clinical study design have been published on the ESMO official website.</p>\n<p>The CS2009 abstract covers only baseline Phase I data from 9 patients as of May 8, 2025 (abstract submission deadline), designed to meet ESMO's abstract submission requirements. At the upcoming ESMO conference, CSTONE PHARMA-B will present preliminary Phase I dose escalation clinical research data for CS2009 in approximately 70 patients with advanced solid tumors in poster format. This will mark the first known global clinical data publication for a PD-1/VEGF/CTLA-4 trispecific antibody.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169589451.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"","article_id":"1174643782","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174643782","pubTimestamp":1760319860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSTONE PHARMA-B (02616) surged over 3%, closing up 2.79% at HK$6.99 with a trading volume of HK$15.38 million as of press time. On the news front, CSTONE PHARMA-B announced that the 2025 European...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","YANG":"三倍做空富时中国ETF-Direxion","BK4614":"Manus概念股","07226":"南方两倍做多恒科","BK4023":"应用软件","BK1161":"生物科技","HSCEI":"国企指数","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","PD":"PagerDuty, Inc.","BK1574":"生物医药B类股","02616":"基石药业-B"},"translate_title":"港股快讯|基石药业-B(02616)涨超3%公司将在ESMO会议上展示PD-1/VEGF/CTLA-4三特异性抗体I期剂量递增临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1,"07226":1,"HSCEI":1,"PD":1,"YANG":1},"content_text":"CSTONE PHARMA-B (02616) surged over 3%, closing up 2.79% at HK$6.99 with a trading volume of HK$15.38 million as of press time.\nOn the news front, CSTONE PHARMA-B announced that the 2025 European Society for Medical Oncology (ESMO) Annual Congress will be held from October 17-21, 2025, in Berlin, Germany. Abstracts for the company's core clinical pipeline candidate CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) ongoing Phase I dose escalation clinical data and CS5001 (ROR1 antibody-drug conjugate [ADC]) ongoing Phase Ib clinical study design have been published on the ESMO official website.\nThe CS2009 abstract covers only baseline Phase I data from 9 patients as of May 8, 2025 (abstract submission deadline), designed to meet ESMO's abstract submission requirements. At the upcoming ESMO conference, CSTONE PHARMA-B will present preliminary Phase I dose escalation clinical research data for CS2009 in approximately 70 patients with advanced solid tumors in poster format. This will mark the first known global clinical data publication for a PD-1/VEGF/CTLA-4 trispecific antibody.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}